Dyskeratosis congenita: Advances in the understanding of the telomerase defect and the role of stem cell transplantation

被引:81
|
作者
de la Fuente, J.
Dyskeratosis, Dokal I.
机构
[1] St Marys Hosp, Dept Paediat, London W2 1NY, England
[2] Barts & London Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, Acad Unit Paediat, London, England
基金
英国惠康基金;
关键词
dyskeratosis congenita; telomerase stem; cell transplantation;
D O I
10.1111/j.1399-3046.2007.00721.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
DC is a multisystem bone marrow failure syndrome exhibiting marked clinical and genetic heterogeneity. X-linked, autosomal dominant and autosomal recessive subtypes are recognized. The gene mutated in X-linked DC (DKC1) encodes a highly conserved nucleolar protein called dyskerin. Dyskerin associates with the H/ACA motif class of small nucleolar RNAs in small nucleolar ribonucleoprotein particles that are important in guiding the conversion of uracil to pseudouracil during the maturation of ribosomal RNA. Dyskerin also associates with the TERC, which is important in the maintenance of telomeres. Mutations in TERC have been identified in patients with autosomal dominant DC and in a subset of patients with aplastic anemia and myelodysplasia. Recently, heterozygous mutations in TERT have been found in some patients with autosomal dominant DC and aplastic anemia. Additionally, patients with the severe multisystem disorder, Hoyeraal-Hreidarsson syndrome, have been found to have DKC1 mutations. Collectively, these observations have demonstrated that classical DC, Hoyeraal-Hreidarsson syndrome and a subset of aplastic anemia are due to a primary defect in telomerase. The critical role of telomeres and telomerase in humans is seen in the multisystem abnormalities found in these patients, including the increased incidence of malignancy. As bone marrow failure is the principal cause of death, conventional allografts have been attempted with limited success due to the high rate of pulmonary and endothelial complications. However, outcomes have improved with the use of non-myeloablative protocols, although the follow up is too short to evaluate long term toxicity and the natural course of the disease and it may be that correction of the telomerase defect is essential for the treatment of these patients.
引用
收藏
页码:584 / 594
页数:11
相关论文
共 27 条
  • [1] Advances in the understanding of dyskeratosis congenita
    Walne, Amanda J.
    Dokal, Inderjeet
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (02) : 164 - 172
  • [2] Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita
    Fioredda, Francesca
    Iacobelli, Simona
    Korthof, Elisabeth T.
    Knol, Cora
    van Biezen, Anja
    Bresters, Dorine
    Veys, Paul
    Yoshimi, Ayami
    Fagioli, Franca
    Mats, Brune
    Zecca, Marco
    Faraci, Maura
    Miano, Maurizio
    Arcuri, Luca
    Maschan, Michael
    O'Brien, Tracey
    Diaz, Miguel A.
    Sevilla, Julian
    Smith, Owen
    de Latour, Regis Peffault
    de la Fuente, Josue
    Or, Reuven
    Van Lint, Maria T.
    Tolar, Jakub
    Aljurf, Mahmoud
    Fisher, Alain
    Skorobogatova, Elena V.
    Diaz de Heredia, Cristina
    Risitano, Antonio
    Dalle, Jean-Hugues
    Sedlacek, Petr
    Ghavamzadeh, Ardeshir
    Dufour, Carlo
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 110 - 118
  • [3] Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita
    Elmahadi, Shaimaa
    Muramatsu, Hideki
    Kojima, Seiji
    CURRENT OPINION IN HEMATOLOGY, 2016, 23 (06) : 501 - 507
  • [4] Reconsidering the indication of haematopoietic stem cell transplantation for dyskeratosis congenita
    Kojima, Seiji
    Ehlert, Karoline
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 11 - 12
  • [5] Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita
    Güngör, T
    Corbacioglu, S
    Storb, R
    Seger, RA
    BONE MARROW TRANSPLANTATION, 2003, 31 (05) : 407 - 410
  • [6] Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita
    T Güngör
    S Corbacioglu
    R Storb
    R A Seger
    Bone Marrow Transplantation, 2003, 31 : 407 - 410
  • [7] Dyskeratosis congenita future: Hematopoietic stem cell transplantation or gene therapy?
    Manoochehrabadi, Saba
    Behfar, Maryam
    Ahmadvand, Mohammad
    Hamidieh, Amir Ali
    GENE REPORTS, 2025, 38
  • [8] Dyskeratosis congenita and limbal stem cell deficiency
    Aslan, Deniz
    Akata, Rustu Fikret
    EXPERIMENTAL EYE RESEARCH, 2010, 90 (03) : 472 - 473
  • [9] Posttransplant Lymphoproliferative Disorder Complicating Hematopoietic Stem Cell Transplantation in a Patient With Dyskeratosis Congenita
    Bohn, Olga L.
    Whitten, Joseph
    Spitzer, Barbara
    Kobos, Rachel
    Prockop, Susan
    Boulad, Farid
    Arcila, Maria
    Wang, Lu
    Teruya-Feldstein, Julie
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2013, 21 (05) : 520 - 525
  • [10] Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita
    Gadalla, Shahinaz M.
    Sales-Bonfim, Carmem
    Carreras, Jeanette
    Alter, Blanche P.
    Antin, Joseph H.
    Ayas, Mouhab
    Bodhi, Prasad
    Davis, Jeffrey
    Davies, Stella M.
    Deconinck, Eric
    Deeg, H. Joachim
    Duerst, Reggie E.
    Fasth, Anders
    Ghavamzadeh, Ardeshir
    Giri, Neelam
    Goldman, Frederick D.
    Kolb, E. Anders
    Krance, Robert
    Kurtzberg, Joanne
    Leung, Wing H.
    Srivastava, Alok
    Or, Reuven
    Richman, Carol M.
    Rosenberg, Philip S.
    de Toledo Codina, Jose Sanchez
    Shenoy, Shalini
    Socie, Gerard
    Tolar, Jakub
    Williams, Kirsten M.
    Eapen, Mary
    Savage, Sharon A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (08) : 1238 - 1243